Evidence map›Paper›PMID 39757425›Full record

ReviewJournal of the International AIDS Society2025

Characterizing populations prioritized for PrEP in 19 African countries: a review of national guidance.

Lauren A Graybill, Caroline N McKay, Jiayu Wang, Nadia A Sam-Agudu, Marcel Yotebieng, Friday Saidi, Linda-Gail Bekker, Bonnie E Shook-Sa, Benjamin H Chi, Nora E Rosenberg

Abstract readReview
In one paragraph

Review in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lauren A GraybillInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-8679-642X
Caroline N McKayDepartment of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jiayu WangDepartment of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-0021-4298
Nadia A Sam-AguduInternational Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-5052-7730
Marcel YotebiengDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Friday SaidiUNC Project Malawi, Lilongwe, Malawi.
Linda-Gail BekkerDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-0755-4386
Bonnie E Shook-SaDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Benjamin H ChiDepartment of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-1435-8455
Nora E RosenbergDepartment of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Training in Sexually Transmitted Infections and HIVT32AI007001 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SENA-SOBERANO, ARLENE C. · 1985 to 2025
$10.9M
Mentoring new investigators in PMTCT implementation researchK24AI120796 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Benjamin H. Chi · 2016 to 2026
$1.3M
Developing a risk assessment tool to identify HIV-uninfected adolescent girls and young women at highest risk for HIV infection: a key step for targeted biomedical HIV preventionR21MH125705 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROSENBERG, NORA · 2021 to 2022
$428k
Developing a regionally representative risk assessment tool to identify men at highest risk of HIV acquisition in sub-Saharan AfricaR21MH134750 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROSENBERG, NORA, SHOOK-SA, BONNIE E · 2023 to 2023
$417k
National Institute of Allergy and Infectious Diseases K24-AI120796National Institute of Allergy and Infectious Diseases P30-AI050410National Institute of Allergy and Infectious Diseases T32-AI007001NIAID NIH HHS K24 AI120796NIAID NIH HHS P30 AI050410NIAID NIH HHS T32 AI007001NIMH NIH HHS R21 MH125705NIMH NIH HHS R21-MH125705NIMH NIH HHS R21 MH134750NIMH NIH HHS R21-MH134750
6 · The paper itself

Abstract

introductionWhile African countries have expanded access to HIV pre-exposure prophylaxis (PrEP) since 2015, regional targets for PrEP uptake remain unmet. Understanding which populations are prioritized for PrEP at the policy level is an important step in determining the scope of PrEP distribution across Africa and identifying gaps in programme implementation. We reviewed national guidance to characterize populations prioritized for PrEP in Africa.

methodsBetween January and June 2023, we searched for current National HIV Treatment and Prevention Guidelines, National HIV Strategic Plans, and the United States President's Emergency Plan for AIDS Relief (PEPFAR) Country Operational Plans (COPs) for all African countries implementing PrEP programmes supported by PEPFAR in 2022. From each document, we summarize the populations prioritized for PrEP within a country and describe PrEP eligibility.

resultsIn 2022, 19 African countries implemented PrEP programmes supported by PEPFAR. Eighteen of these countries contributed National Guidelines (2016-2022), 18 contributed National Strategic Plans (2017-2023) and 19 contributed COPs (2022) to this review. Twenty-nine population groups were prioritized for PrEP in these documents. All countries prioritized HIV-serodifferent couples, female sex workers (FSWs), adolescent girls and young women (AGYW), pregnant and breastfeeding women (PBFW) and people who inject drugs (PWID), and most prioritized men who have sex with men (MSM; n = 18), transgender people (n = 18) and people in prisons (n = 17). The remaining 21 populations were prioritized in fewer than two-thirds of countries. DISCUSSION: FSWs, MSM, PWID, transgender people and people in prisons were typically prioritized for PrEP with no eligibility restrictions. In contrast, most countries had at least one document indicating that HIV-serodifferent couples, AGYW and PBFW were only eligible for PrEP if classified as high risk. Few documents specified how risk was determined, and no document included validated HIV risk assessment tools to guide implementation. We observed similarities in priority populations across countries with different HIV epidemics and inconsistencies in who was prioritized for PrEP within a country's own set of policy documents.

conclusionsUnderstanding how PrEP prioritization policies impact HIV incidence in different epidemiologic settings is critical for strengthening PrEP implementation across the continent.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentAdultAfricaFemaleHealth PolicyHumansMalePregnancySex WorkersYoung AdultAnti-HIV AgentsAfricaHIV preventionoperational and implementation sciencespolicy reviewpre‐exposure prophylaxispriority populations

Identifiers

PMID39757425
PMCPMC11702491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.